Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00758498 · ClinicalTrials.gov registry record · Phase 3
Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder
A Phase 3 study of Excessive Sleepiness, sponsored by Cephalon.
- Completed
- Registry status
- Phase 3
- Development phase
- 427
- Enrollment target
- 4
- Study locations
NCT00758498 is a Phase 3 study of Excessive Sleepiness that has completed, run by Cephalon. The registered enrollment target is 427 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT00758498, a Phase 3 study of Excessive Sleepiness, has completed, sponsored by Cephalon.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 427 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled, parallel-group study of armodafinil and placebo treatment in healthy subjects with excessive sleepiness associated with jet lag disorder.
Conditions Studied
Interventions
- DRUG placebo
- DRUG armodafinil
Study Locations (4)
Georgia
- Neurotrials Research, Inc. - Atlanta
Kentucky
- Community Research - Crestview
New York
- Clinilabs, Inc. - New York
South Carolina
- SleepMed of South Carolina - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 427 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00758498
The ClinicalTrials.gov registry entry for NCT00758498 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 427 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cephalon, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Excessive Sleepiness appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00758498 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Georgia, Kentucky, New York.
Frequently Asked Questions
What is clinical trial NCT00758498 about?
NCT00758498 is a clinical study titled "Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder". This is a randomized, double-blind, placebo-controlled, parallel-group study of armodafinil and placebo treatment in healthy subjects with excessive sleepiness associated with jet lag disorder.
What is the current status of trial NCT00758498?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 427 participants. The study started on 2008-09. Estimated completion is 2009-02.
What conditions does trial NCT00758498 study?
This clinical trial studies the following conditions: Excessive Sleepiness.
What interventions are being tested in trial NCT00758498?
The interventions under investigation include: placebo (DRUG), armodafinil (DRUG).
Who is sponsoring clinical trial NCT00758498?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00758498 being conducted?
This trial has 4 study locations across Georgia, Kentucky, New York, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Excessive Sleepiness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.